Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

NCT01559129 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment was stopped early (see limitations and caveats section).

Conditions

Scleroderma, Systemic
Sclerosis, Systemic
Systemic Scleroderma
Systemic Sclerosis
Interstitial Lung Disease

Interventions

DRUG: Pomalidomide (CC-4047)
DRUG: Placebo

Sponsor

Celgene